🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s BMRN Holdings & Trades

First Buy
Q2 2014
Duration Held
36 Quarters
Largest Add
Q3 2020
+943,693 Shares
Current Position
438,817 Shares
$26.08 M Value

Steven Cohen's BMRN Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 438,817 shares of BioMarin Pharmaceutical Inc. (BMRN) worth $26.08 M, representing 0.03% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 36 quarters.

Based on 13F filings, Steven Cohen has maintained a strategic position in BMRN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2020, adding 943,693 shares. Largest reduction occurred in Q2 2024, reducing 1.35 M shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's BioMarin Pharmaceutical (BMRN) Holding Value Over Time

Track share changes against reported price movement

Quarterly BioMarin Pharmaceutical (BMRN) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +438,817 New Buy 438,817 $59.43
Q2 2025 -395,750 Sold Out 0 $0.00
Q1 2025 +129,314 Add 48.53% 395,750 $70.69
Q4 2024 +68,718 Add 34.76% 266,436 $65.73
Q3 2024 +197,718 New Buy 197,718 $70.29
Q2 2024 -1.35 M Sold Out 0 $0.00
Q1 2024 +890,420 Add 195.57% 1.35 M $87.34
Q4 2023 +455,300 New Buy 455,300 $96.42
Q1 2023 -716,700 Sold Out 0 $0.00
Q4 2022 +121,300 Add 20.37% 716,700 $103.49
Q3 2022 +447,529 Add 302.65% 595,400 $84.77
Q2 2022 -218,965 Reduce 59.69% 147,871 $82.87
Q1 2022 -454,960 Reduce 55.36% 366,836 $77.10
Q4 2021 +30,007 Add 3.79% 821,796 $88.35
Q3 2021 +425,289 Add 116.04% 791,789 $77.29
Q2 2021 +110,000 Add 42.88% 366,500 $83.44
Q1 2021 -124,600 Reduce 32.69% 256,500 $75.51
Q4 2020 -562,593 Reduce 59.62% 381,100 $87.69
Q3 2020 +943,693 New Buy 943,693 $76.08
Q1 2020 -260,683 Sold Out 0 $0.00
Q4 2019 +196,010 Add 303.08% 260,683 $84.55
Q3 2019 -186,973 Reduce 74.30% 64,673 $67.40
Q2 2019 +251,646 New Buy 251,646 $85.65
Q3 2018 -53,703 Sold Out 0 $0.00
Q2 2018 -198,397 Reduce 78.70% 53,703 $94.20
Q1 2018 -245,249 Reduce 49.31% 252,100 $81.07
Q4 2017 -272,193 Reduce 35.37% 497,349 $89.17
Q3 2017 +769,542 New Buy 769,542 $93.07
Q2 2017 -364,800 Sold Out 0 $0.00
Q1 2017 -161,800 Reduce 30.73% 364,800 $87.78
Q4 2016 +372,900 Add 242.62% 526,600 $82.84
Q3 2016 +153,700 New Buy 153,700 $92.52
Q1 2015 -74,600 Sold Out 0 $0.00
Q4 2014 -601,000 Reduce 88.96% 74,600 $90.40
Q3 2014 +585,500 Add 649.83% 675,600 $72.16
Q2 2014 +90,100 Add 0.00% 90,100 $62.21

Steven Cohen's BioMarin Pharmaceutical Investment FAQs

Steven Cohen first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q2 2014, acquiring 90,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held BioMarin Pharmaceutical Inc. (BMRN) for 36 quarters since Q2 2014.

Steven Cohen's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q3 2020, adding 943,693 shares worth $71.8 M.

According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 438,817 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $26.08 M.

As of the Q4 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.03% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 1,345,720 shares, as reported at the end of Q1 2024.